Bausch + Lomb Posts 7% Revenue Growth, Raises 2026 Guidance

What happened

Bausch + Lomb reported third-quarter 2026 revenue of $1.375 billion, up 7% from a year earlier, with net income of $32 million and adjusted EBITDA of $325 million. The company also raised its full-year revenue and adjusted EBITDA guidance.

Confirmed

Global impact / market context

Higher revenue across all three segments plus a larger profit measure gives the company more cash to fund operations and pay down obligations. The raised outlook suggests management expects the stronger demand to continue, which can support the share price.

Analyst inference

Growth was led by eye-care products: MIEBO rose 42% and LUMIFY 35%, while daily SiHy contact lenses grew 24%. This mix matters because fast-growing branded products can lift profit per sale and offset slower parts of the portfolio.

Analyst inference

What to watch

1. Full-year revenue is now guided to $5.450 billion–$5.550 billion, and adjusted EBITDA excluding acquired IPR&D is guided to $1.090 billion–$1.140 billion. Confirmed
2. Investors could compare future quarters against this raised guidance, since missing the new revenue or adjusted EBITDA ranges would signal weaker demand than management now expects. Proposed
3. Watch whether MIEBO and LUMIFY keep growing near their current rates, because those brands appear to be the main drivers lifting profit per sale. Analyst inference

Evidence

• Original source link unavailable